Lineage Cell Therapeutics Inc

LCTX

1.700USD

+0.020+1.19%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

Lineage Cell Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

76 / 392

Overall Ranking

197 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Lineage Cell Therapeutics Inc Highlights

StrengthsRisks

Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological and ophthalmic conditions. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, it designs, develops, manufactures, and tests specialized human cells with anatomical and physiological functions. Its neuroscience focused pipeline includes OpRegen, a retinal pigment epithelial cell therapy in phase II a development, for the treatment of geographic atrophy secondary to age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy in phase I/II a development for the treatment of spinal cord injuries; ANP1, an auditory neuronal progenitor cell therapy for the potential treatment of auditory neuropathy; PNC1, a photoreceptor neural cell therapy for the potential treatment of vision loss due to photoreceptor dysfunction or damage; and RND1.

Growing

The company is in a growing phase, with the latest annual income totaling USD 9.50M.

Overvalued

The company’s latest PE is -5.79, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 95.70M shares, decreasing 22.32% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 9.64M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.05.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

4.167

Target Price

+148.02%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Lineage Cell Therapeutics Inc is 7.59, ranking 95 out of 392 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 3.68M, representing a year-over-year decrease of 2.59%, while its net profit experienced a year-over-year decrease of 881.58%.

Score

Industry at a Glance

Previous score

7.59

Change

0



Financials

6.28

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.79

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.60

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.26

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Lineage Cell Therapeutics Inc is 6.55, ranking 255 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -5.79, which is -21.63% below the recent high of -4.54 and -147.02% above the recent low of -14.30.

Score

Industry at a Glance

Previous score

6.55

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 76/392

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Lineage Cell Therapeutics Inc is 8.00, ranking 164 out of 392 in the Biotechnology & Medical Research industry. The average price target is 3.00, with a high of 9.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Lineage Cell Therapeutics Inc is 8.94, ranking 46 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.85 and the support level at 1.50, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.82

Change

0.12

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Lineage Cell Therapeutics Inc is 3.00, ranking 197 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 41.55%, representing a quarter-over-quarter decrease of 1.77%. The largest institutional shareholder is The Vanguard, holding a total of 9.64M shares, representing 4.19% of shares outstanding, with 7.20% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Broadwood Capital, Inc.

49.56M

--

Chernett (Jorey)

11.45M

--

The Vanguard Group, Inc.

Star Investors

9.01M

+6.18%

Defender Capital LLC

6.81M

+0.32%

Raffles Capital Management, LLC

5.39M

-0.08%

Comerica, Inc.

4.60M

--

Millennium Management LLC

2.68M

+3.05%

Geode Capital Management, L.L.C.

2.42M

-0.49%

BlackRock Institutional Trust Company, N.A.

2.23M

-1.33%

Renaissance Technologies LLC

Star Investors

1.91M

-3.38%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Lineage Cell Therapeutics Inc is 3.81, ranking 119 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 1.77. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. Lineage Cell Therapeutics Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.

Lineage Cell Therapeutics Inc

LCTX

6.95 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.53 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ionis Pharmaceuticals Inc

IONS

8.38 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.37 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.17 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment